Drug Information

Drug (ID: DG02171) and It's Reported Resistant Information

• Name: Peg-Loxenatide
• Synonyms: Peg-Loxenatide
• Indication:
  In total 1 Indication(s)
  . .; .; [1]

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-05: Endocrine/nutritional/metabolic diseases

Type 2 diabetes mellitus [ICD-11: 5A11]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: Transforming protein RhoA (RHOA) [1]

• Sensitive Disease: Type 2 diabetes mellitus [ICD-11: 5A11.0]
• Molecule Alteration: Expression; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Hepatic cells; Liver; Homo sapiens (Human); N.A.
• In Vivo Model: Sprague-Dawley rats model; Rattus norvegicus
• Experiment for Molecule Alteration: Immunohistochemistry; ELISA assay; RNA immunoprecipitation assay; RT-qPCR; Western blot assay
• Experiment for Drug Resistance: Fasting blood glucose level testing; Oral glucose tolerance testing; Biochemical assay; Reactive oxygen species assay
• Mechanism Description: PEG-Loxe mitigated inflammatory response and oxidative stress. High-PEG-Loxe reduced RhoA and Rho-associated coiled-coil kinase 2 (ROCK2) in liver tissues of type 2 diabetes mellitus rats, while both doses of PEG-Loxe decreased steroid receptor RNA activator (SRA). SRA overexpression reversed the protective functions of high-PEG-Loxe. SRA cooperated with cellular nucleic acid binding protein (CNBP) to enhance ROCK2 mRNA stability.High-PEG-Loxe relieves insulin resistance and lipid metabolism disorder in type 2 diabetes mellitus through SRA/CNBP/ROCK2 axis. This research provides a molecular mechanism of PEG-Loxe for treating type 2 diabetes mellitus.

Key Molecule: Rho associated coiled-coil containing protein kinase 2 (ROCK2) [1]

• Sensitive Disease: Type 2 diabetes mellitus [ICD-11: 5A11.0]
• Molecule Alteration: Expression; Down-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: Hepatic cells; Liver; Homo sapiens (Human); N.A.
• In Vivo Model: Sprague-Dawley rats model; Rattus norvegicus
• Experiment for Molecule Alteration: Immunohistochemistry; ELISA assay; RNA immunoprecipitation assay; RT-qPCR; Western blot assay
• Experiment for Drug Resistance: Fasting blood glucose level testing; Oral glucose tolerance testing; Biochemical assay; Reactive oxygen species assay
• Mechanism Description: PEG-Loxe mitigated inflammatory response and oxidative stress. High-PEG-Loxe reduced RhoA and Rho-associated coiled-coil kinase 2 (ROCK2) in liver tissues of type 2 diabetes mellitus rats, while both doses of PEG-Loxe decreased steroid receptor RNA activator (SRA). SRA overexpression reversed the protective functions of high-PEG-Loxe. SRA cooperated with cellular nucleic acid binding protein (CNBP) to enhance ROCK2 mRNA stability.High-PEG-Loxe relieves insulin resistance and lipid metabolism disorder in type 2 diabetes mellitus through SRA/CNBP/ROCK2 axis. This research provides a molecular mechanism of PEG-Loxe for treating type 2 diabetes mellitus.

References

• Ref 1: Polyethylene glycol loxenatide modulates lipid metabolism and insulin resistance through lncRNA steroid receptor RNA activator/cellular nucleic acid binding protein/Rho-associated coiled-coil kinase 2 axis in type 2 diabetes mellitus. J Diabetes Investig. 2025 Apr;16(4):715-727.